<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01756521</url>
  </required_header>
  <id_info>
    <org_study_id>MOXI036</org_study_id>
    <nct_id>NCT01756521</nct_id>
  </id_info>
  <brief_title>A Study Study to Investigate the Effect on QT/QTc Interval of Moxifloxacin After a Single Dose in Healthy Male Subjects</brief_title>
  <official_title>A Multi-center, Randomized, Open-label, Placebo-controlled, 3-way Crossover Study to Investigate the Effect on QT/QTc Interval of Moxifloxacin After a Single Dose in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korea National Enterprise for Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate effect of moxifloxacin on QT/QTc interval in healthy
      male subjects. Moxifloxacin is a positive control drug used in QT study. In this study,
      moxifloxacin 400mg and 800mg will be used, to get information on effect of moxifloxacin on
      QT/QTc interval.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate effect of moxifloxacin on QT/QTc interval in healthy
      male subjects. Moxifloxacin is a positive control drug used in QT study. In this study,
      moxifloxacin 400mg and 800mg will be used, (therapeutic and supratherapeutic doses) to get
      information on effect of moxifloxacin on QT/QTc interval in healthy Korean male subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QTc (QTcF, QTcB, QTcI)</measure>
    <time_frame>Day1 and Day2 of each periods(3 periods)</time_frame>
    <description>QTc (QTcF, QTcB, QTcI)
QTcF (Fridericia-corrected QTc)
QTcB (Bazett-corrected QTc)
QTcI (Individual-corrected QTc)
QTc change: the largest time-matched, baseline-adjusted least squares mean difference time-matched, baseline-adjusted least squares mean difference</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>the Effect of Moxifloxacin on QT/QTc Interval</condition>
  <arm_group>
    <arm_group_label>Moxifloxacin 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>moxifloxacin 400mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin 800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>moxifloxacin 800mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo(No treatment)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Only drink water</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <arm_group_label>Moxifloxacin 400mg</arm_group_label>
    <arm_group_label>Moxifloxacin 800mg</arm_group_label>
    <arm_group_label>Placebo(No treatment)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy male subject aged 20 to 40 at screening

          -  subjects who have weight over 50 kg with ideal body weight range of +- 20%

          -  subjects who decide to participate voluntarily and write a informed consent form

        Exclusion Criteria:

          -  subjects who have acute illness within 28 days of investigational drug administration

          -  subjects who have clinically significant disease of cardiovascular, respiratory,
             renal, endocrinological, hematological, gastrointestinal, neurological(central nervous
             system), psychiatric disorders or malignant tumor

          -  subjects who have determined not eligible by screening test (medical history, physical
             examination, 12-lead ECG, laboratory test, etc) within 28 days of study start

          -  clinically significant allergic disease (except for mild allergic rhinitis)

          -  systolic blood pressure&gt;= 140 mmHg, diastolic blood pressure &gt;= 90 mmHg, heart rate &gt;
             100 bpm or &lt; 50 bpm

          -  result of 12-lead electrocardiogram includes :

               -  QTcF &gt; 450 msec

               -  PR interval &gt; 200 msec or &lt;110msec

               -  Evidence of second- or third-degree atrioventricular (AV) block

               -  Pathologic Q waves (defined as Q-wave &gt; 40 msec or depth &gt; 0.5 millivolt

               -  Evidence of ventricular pre-excitation, left bundle branch block (LBBB), right
                  bundle branch block (RBBB)

               -  Intraventricular conduction delay with QRS &gt; 120 msec

          -  risk of Torsade de pointes such as long QT syndrome, family history of sudden death,
             heart failure, hypokalemia

          -  Subjects considered unsuitable for inclusion by the investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital and College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://ctc.snuh.org</url>
    <description>webpage of clinical trial center of Seoul National University Hospital</description>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2012</study_first_submitted>
  <study_first_submitted_qc>December 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2012</study_first_posted>
  <last_update_submitted>April 25, 2016</last_update_submitted>
  <last_update_submitted_qc>April 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Kyung-Sang Yu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>QT,</keyword>
  <keyword>QTc,</keyword>
  <keyword>electrocardiogram,</keyword>
  <keyword>moxifloxacin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

